Pharmacokinetic study and safety assessment of lacosamide tablets in Chinese healthy subjects under fasting condition

doi:10.12092/j.issn.1009-2501.2019.02.012

Abstract

Abstract:

AIM: To investigate the pharmacokinetic properties and safety of a single dose of 100 mg of lacosamide tablets in Chinese healthy subjects under fasting condition. METHODS: One single-dose, open-label, randomized and crossover study of oral lasosamide tablets was conducted in 24 healthy subjects,who were administrated test or reference preparation 100 mg under fasting condition. After a washout period of 7 days, the subjects were orally administrated with another preparation. Plasma samples were collected before and after each 24 subjects given a tablet.Concentrations of lacosamide were determined by LC-MS/MS. Pharmacokinetic parameters, including AUC0-t，AUC0-∞，Cmax，etc., were calculated with WinNonlin 6.3. Safety assessment was performed throughout the experiment. Vital signs, laboratory tests and adverse events were recorded, which was used to assess the safety of preparations.RESULTS:All 24 subjects completed the trial and were taken into pharmacokinetic analysis and safety judgment. The main pharmacokinetic parameters of the two preparations, including AUC0-t,AUC0-∞,Cmax, were basically consistent and no significant differences were found. The overall incidence of adverse events during the trial was 50%. The incidence of adverse events of the test preparation was 12.5%, and that of reference preparation was 4.2%. The severity of all adverse events was grade 1 and there was no serious adverse events observed.CONCLUSION: Domestic lacomide tablet has good safety and tolerance in Chinese healthy volunteers, and its pharmacokinetic parameters are basically same as that of imported drugs.

Key words: lacosamide, pharmacokinetics, safety, LC-MS/MS

CLC Number:

R969.1

KANG Hui, YONG Xiaolan, HU Tingting, CHU Bixin, WANG Lantian. Pharmacokinetic study and safety assessment of lacosamide tablets in Chinese healthy subjects under fasting condition[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 192-197.

References

［1］Bainbridge J, De Backer M, Eckhardt K, et al. Safety and tolerability of lacosamide monotherapy in the elderly: A subgroup analysis from lacosamide trials in diabetic neuropathic pain［J］.Epilepsia Open, 2017, 2(4):415-423.
［2］Sanmartí-Vilaplana F, Díaz-Gómez A. The effectiveness and safety of lacosamide in children with epilepsy in a clinical practice setting［J］. Epilepsy Behav, 2018, 79:130-137.
［3］吴欣桐，孙红斌，王为民，等.拉科酰胺片添加治疗癫痫部分发作的安全性和有效性研究［J］.癫痫杂志，2015，1（1）：5-16.
［4］U.S.Department of Health and Human Services,National Institutes of Health,National Cancer Institute.Common terminology criteria for adverse events［EB/OL］.http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf,2010-06-14.
［5］FDA.Highlights of prescribing information［EB/OL］.(2017-11-07).www.accessdata.fda.gov/drugsalfda_docs/label/2017/022253s039,022254s030,022355s022lbl.pdf.
［6］Zaccara G, Perucca P, Loiacono G, et al.The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials［J］.Epilepsia, 2013, 54(1):66-74.
［7］Sunwoo JS, Byun JI, Lee SK.A case of lacosamide-induced hepatotoxicity［J］.Int J Clin Pharmacol Ther, 2015, 53(6):471-473.
［8］Ben-Menachem E, Biton V, Jatuzis D, et al.Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures［J］. Epilepsia, 2007, 48(7):1308-1317.
［9］Shaibani A, Fares S, Selam J. et al. Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial［J］. J Pain, 2009, 10(8):818-828.
［10］DeGiorgio CM. Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures［J］. Epilepsy Behav, 2010, 18(3):322-324.
［11］Kaufman KR, Velez AE, Wong S, et al. Low-dose lacosamide-induced atrial fibrillation: Case analysis with literature review［J］.Epilepsy Behav Case Rep, 2012, 1:22-25.
［12］Luk ME, Tatum WO, Patel AV, et al.The safety of lacosamide for treatment of seizures and seizure prophylaxis in adult hospitalized patients［J］. Neurohospitalist, 2012, 2(3):77-81.
［13］Delaunois A, Colomar A, Depelchin BO, et al.Cardiac safety of lacosamide: the non-clinical perspective［J］. Acta Neurol Scand, 2015, 132(5):337-345.
［14］Kropeit D, Johnson M, Cawello W, et al.Lacosamide cardiac safety: a thorough QT/QTc trial in healthy volunteers［J］. Acta Neurol Scand, 2015, 132(5):346-354.
［15］Rudd GD, Haverkamp W, Mason JW, et al.Lacosamide cardiac safety: clinical trials in patients with partial-onset seizures［J］. Acta Neurol Scand, 2015, 132(5):355-363.
［16］Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures［J］. Epilepsia, 2007, 48(7):1308-1317.
［17］Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial［J］. Epilepsia, 2010, 51(6):958-967.
［18］Halász P, Klviinen R, Mazurkiewicz-Beldzińska M, et al. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial［J］.Epilepsia, 2009, 50(3):443-453.

[1]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[2]	XIAO Yue, LI Tangfei, XUE Qianfu. Analysis of the efficacy and safety of Peg-IFN-α in the treatment of essential thrombocythemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1049-1055.
[3]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[4]	HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun. Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 498-507.
[5]	HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
[6]	LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
[7]	YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177.
[8]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[9]	ZHOU Jiating, ZHANG Xuan, XIE Zilan, LI Zhi. Interactions and clinical significance of gut microbiota and levothyroxine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1307-1314.
[10]	JIA Boying, ZHOU Shuang, WAN Liyan, ZHOU Ying, CUI Yimin. Drug-induced dysphagia risk in elder people——A pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) database [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1109-1120.
[11]	LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
[12]	LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HUANG Kai. Safety analysis on bioequivalence studies of orally inhaled drug products in healthy Chinese subjects#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1131-1138.
[13]	WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145.
[14]	MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling. Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918.
[15]	LIANG Meifang, CHEN Qingzhuang, YANG Peiqun, WANG Yong. Efficacy and safety of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack: A real-world study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 785-792.